Small molecule · developed by LB Pharmaceuticals
LB-102 is an oral tablet studied in schizophrenia, given at flexible doses of 50 mg to 100 mg over six weeks in the trial sources.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07369154 | Phase 3 | Schizophrenia | Recruiting | LBRX |
| NCT07363577 | Phase 3 | Schizophrenia | Recruiting | LBRX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Schizophrenia